Skip to main content
590 search results for:

Guselkumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 12-03-2024 | Guselkumab | OriginalPaper

    Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis

    Psoriatic arthritis (PsA) is an inflammatory musculoskeletal and cutaneous disease with heterogenous clinical presentation and variable course. Musculoskeletal manifestations include enthesitis and dactylitis along with peripheral arthritis and …

  2. Open Access 15-03-2024 | Guselkumab | Online First

    Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

    Approximately 30% of patients with psoriasis develop psoriatic arthritis (PsA), a chronic and systemic disease characterized by inflammation across a range of tissue domains, particularly cutaneous and musculoskeletal [ 1 ]. According to the …

  3. Open Access 04-03-2024 | Guselkumab | Online First

    The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study

    Psoriatic arthritis (PsA) is a chronic disease characterized by inflammatory musculoskeletal manifestations in patients with psoriasis [ 1 ]. This disorder is associated with heterogeneous clinical manifestations variously involving peripheral …

  4. Open Access 22-02-2024 | Guselkumab | OriginalPaper

    Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis

    Psoriatic arthritis (PsA) is a chronic inflammatory disease that can lead to substantial impairment in physical function and a high degree of disability [ 1 – 3 ], reflecting symptomatology across a variety of affected domains, such as skin …

  5. Open Access 28-02-2024 | Guselkumab | OriginalPaper

    Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials

    Treatment for psoriatic arthritis (PsA), a chronic inflammatory condition, has evolved from traditional disease-modifying antirheumatic drugs (DMARDs) to targeted synthetic and biologic DMARDs [ 1 , 2 ]. Specifically, biologic therapies that …

  6. Open Access 01-02-2024 | Guselkumab | OriginalPaper

    Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)

    With increasing availability of novel biologics with new targets for psoriasis, the complexity of choosing the appropriate biologic treatment is ever more challenging for physicians. This applies not only to choosing the most appropriate treatment …

  7. 01-12-2023 | Guselkumab | News

    Guselkumab

    Various toxicities: 7 case reports
  8. Open Access 09-02-2024 | Ixekizumab | OriginalPaper

    Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)

    An interactive infographic provided for this article: https://vahub.lilly.com/gooderham_dermatologyandtherapy_2024 .

  9. Guselkumab

    Itching, diarrhoea and inflammatory bowel disease: 3 case reports
  10. 01-10-2023 | Psoriatic Arthritis | News

    Guselkumab

    Treatment failure: case report
  11. Open Access 07-10-2023 | Vulgar Psoriasis | OriginalPaper

    Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial

    Plaque psoriasis is the most common form of psoriasis [ 1 ] and the concept of this highly prevalent disease [ 2 , 3 ] involving accumulating disease memory and increasing impact of chronification is now well established [ 4 ]. However, further …

  12. Open Access 03-10-2023 | Psoriatic Arthritis | OriginalPaper

    Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment

    Psoriatic arthritis (PsA) is a complex inflammatory disease affecting peripheral and axial joints, entheses, and tendons, as well as skin and nails [ 1 ]. Structural joint damage occurs in up to half of patients with PsA within 2 years of …

  13. Open Access 07-09-2023 | Psoriasis Guttata | OriginalPaper

    Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab

    Guselkumab is an anti-interleukin-23 monoclonal antibody that is approved for plaque psoriasis and psoriatic arthritis. We present a case of a 28-year-old female patient with acute onset of guttate psoriasis after a blistering sunburn. She had no …

  14. 01-05-2023 | Plaque Psoriasis | News

    Guselkumab

    Diarrhoea: case report
  15. Open Access 31-10-2023 | Psoriatic Arthritis | OriginalPaper

    Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis

    Psoriatic disease is a chronic, systemic, inflammatory disorder that includes psoriasis, psoriatic arthritis (PsA), and associated metabolic, cardiovascular, and psychosocial comorbidities [ 1 – 3 ]. Uncontrolled psoriatic disease can substantially …

  16. Open Access 01-12-2023 | Adalimumab | Erratum

    Correction: Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

  17. Open Access 15-09-2023 | Vulgar Psoriasis | Report

    Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis

    Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease characterized by skin and musculoskeletal involvement. Current treatment recommendations consider the six PsA domains: peripheral arthritis, axial disease, enthesitis …

  18. Open Access 26-09-2023 | Secukinumab | Letter

    Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

  19. Open Access 26-09-2023 | Secukinumab | Letter

    Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

    When considering treatment pattern data, it is important to keep in mind that variability in definitions and methodologies employed among studies can lead to drastically different results, even when using the same data source. This makes it …

  20. Open Access 26-09-2023 | Vulgar Psoriasis | OriginalPaper

    Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2

    Psoriasis is a serious global problem, with reported country prevalences ranging from 0 to 11.43% [ 1 ] and East Asian countries reporting an increasing prevalence of this chronic condition [ 2 , 3 ]. Studies of psoriasis prevalence in China …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.